Dr. Mark Schiller to present “The use of PEER to Personalize Medicine” at IPEG

Print
| Source: MYnd Analytics, Inc.

NIJMEGEN, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. ("MYnd") (OTCQB:MYAN), Dr. Mark Schiller, Medical Director - MYnd Analytics, will present at the International Pharmaco-EEG Society’s (IPEG) 19th Biennial Conference on “The Use of Psychiatric Encephalography Evaluation Registry (PEER) to personalize pharmacotherapy.”

“The PEER Report is in the forefront of providing physicians new personalized medicine tools to add objective physical and biometric findings to psychiatric treatment,” said Dr. Schiller.  His presentation will focus on his own experience with PEER, and a summary of results from four randomized, controlled, double blind trials demonstrating the efficacy of PEER technology in improving patient outcomes.

IPEG is composed of scientists and researchers actively involved in electrophysiological brain research. “We are pleased to have opportunities to educate physicians on PEER technology which can be added to their practices,” said CEO of MYnd Analytics, George Carpenter.

PEER is a predictive medicine technology developed by MYnd which combines an EEG scan of brain function with the largest registry of long-term outcomes in the world to assist physicians in selecting the medication class and agent which is most likely to work on a specific patient’s brain.

About MYnd Analytics, Inc.

MYnd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG).  Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Media Contact:
Lauren Jenkins
ScoutComms
(202) 596-5669